The purpose of this study is to determine if an investigational medication taken by mouth, called zasocitinib, is safe and works better than deucravacitinib for patients who have moderate to severe plaque psoriasis.
At each visit, you will meet with a member of the study team and fill out questionnaires. The study also involves vital signs, blood draws, urine testing, physical exams, ECGs, and a Chest x-ray. You must provide a complete medical history and medication use. Women of child bearing potential will be required to use a birth control method approved by the study. Participants must be willing to take the study medication every day during the study.
Additional information can be provided upon request
Dermatology Clinical Trials Unit (DCTU)
UNC Dermatology and Skin Cancer Center at Southern Village
410 Market St Ste 362, Chapel Hill, NC 27516, USA
Laura Ferris
Dermatology-Research
Clinical or Medical
Interventional
Skin, Hair, and Nails
25-0871
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
